Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer-Reference-Cited by-同舟云学术

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Published:2020-02-12 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Perrone Emanuele,Lopez Salvatore,Zeybek Burak,Bellone Stefania,Bonazzoli Elena,Pelligra Silvia,Zammataro Luca,Manzano Aranzazu,Manara Paola,Bianchi Anna,Buza Natalia,Tymon-Rosario Joan,Altwerger Gary,Han Chanhee,Menderes Gulden,Ratner Elena,Silasi Dan-Arin,Azodi Masoud,Hui Pei,Schwartz Peter E.,Scambia Giovanni,Santin Alessandro D.

Funder

National Institutes of Health

Stand Up To Cancer

Deborah Bunn Alley Ovarian Cancer Research Foundation

Honorable Tina Brozman Foundation

Discovery To Cure

Fondazione Guido Berlucchi

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference32 articles.